Literature DB >> 18818416

Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice.

Min Yang1, Jiusong Sun, Tinghu Zhang, Jian Liu, Jie Zhang, Michael A Shi, Froogh Darakhshan, Michèle Guerre-Millo, Karine Clement, Bruce D Gelb, Gregory Dolgnov, Guo-Ping Shi.   

Abstract

OBJECTIVE: Previous studies demonstrated increased levels of cysteine proteases cathepsins in serum and adipose tissues from obese patients. We now provide evidence from a mouse model of obesity to suggest a direct participation of cathepsin K (CatK) in mouse body weight gain and glucose metabolism. METHODS AND
RESULTS: Using real-time polymerase chain reaction, we detected 12-fold increase in CatK transcripts after adipogenesis of human preadipocytes. Using an immunohistology analysis, we consistently observed high levels of CatK expression in adipose tissues from obese humans and mice. Selective inhibition of CatK activity blocked the lipid accumulation in human and mouse preadipocytes. In mice, CatK deficiency reduced significantly diet-induced body weight gain and serum glucose and insulin levels. Similar results were obtained in diet-induced and genetically created (ob/ob) obese mice after animals were treated with a CatK-selective inhibitor. Mechanistic study demonstrated a role for CatK in degrading fibronectin, a matrix protein that controls adipogenesis. Deficiency or inhibition of CatK leads to fibronectin accumulation in muscle and adipose tissues.
CONCLUSIONS: This study demonstrates an essential role of CatK in adipogenesis and mouse body weight gain, possibly via degradation of fibronectin, thus suggesting a novel therapeutic strategy for the control of obesity by regulating CatK activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818416      PMCID: PMC2736686          DOI: 10.1161/ATVBAHA.108.172320

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  26 in total

1.  Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors.

Authors:  Eva Altmann; Johanne Renaud; Jonathan Green; David Farley; Brian Cutting; Wolfgang Jahnke
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

2.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization.

Authors:  Carey N Lumeng; Jennifer L Bodzin; Alan R Saltiel
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 3.  Thyroid hormone metabolism in obesity.

Authors:  E Roti; R Minelli; M Salvi
Journal:  Int J Obes Relat Metab Disord       Date:  2000-06

4.  Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity.

Authors:  Yin Xiao; Han Junfeng; Luo Tianhong; Wang Lu; Chen Shulin; Zhao Yu; Li Xiaohua; Jian Weixia; Zheng Sheng; Gu Yanyun; Li Guo; Luo Min
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

5.  Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D.

Authors:  Francois Authier; Mourad Metioui; Sylvie Fabrega; Mostafa Kouach; Gilbert Briand
Journal:  J Biol Chem       Date:  2002-01-04       Impact factor: 5.157

6.  Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors.

Authors:  Dong Wang; Michal Pechar; Weijie Li; Pavla Kopecková; Dieter Brömme; Jindrich Kopecek
Journal:  Biochemistry       Date:  2002-07-16       Impact factor: 3.162

7.  Cathepsin L activity controls adipogenesis and glucose tolerance.

Authors:  Min Yang; Yaou Zhang; Jiehong Pan; Jiusong Sun; Jian Liu; Peter Libby; Galina K Sukhova; Alessandro Doria; Nobuhiko Katunuma; Odile D Peroni; Michèle Guerre-Millo; Barbara B Kahn; Karine Clement; Guo-Ping Shi
Journal:  Nat Cell Biol       Date:  2007-07-22       Impact factor: 28.824

8.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice.

Authors:  Galina K Sukhova; Yaou Zhang; Jie-Hong Pan; Youichiro Wada; Takashi Yamamoto; Makoto Naito; Tatsuhiko Kodama; Sotirios Tsimikas; Joseph L Witztum; Michael L Lu; Yasuhiko Sakara; Michael T Chin; Peter Libby; Guo-Ping Shi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin.

Authors:  C Tepel; D Brömme; V Herzog; K Brix
Journal:  J Cell Sci       Date:  2000-12       Impact factor: 5.285

10.  Identification of cathepsin K as a novel marker of adiposity in white adipose tissue.

Authors:  Chiara Chiellini; Mario Costa; Silvia E Novelli; Ez-Zoubir Amri; Luca Benzi; Anna Bertacca; Paul Cohen; Stefano Del Prato; Jeffrey M Friedman; Margherita Maffei
Journal:  J Cell Physiol       Date:  2003-05       Impact factor: 6.384

View more
  32 in total

Review 1.  Adipose tissue remodeling in pathophysiology of obesity.

Authors:  Mi-Jeong Lee; Yuanyuan Wu; Susan K Fried
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

Review 2.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

3.  Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.

Authors:  Yusuke Izumi; Mutsuharu Hayashi; Ryota Morimoto; Xian Wu Cheng; Hongxian Wu; Hideki Ishii; Yoshinari Yasuda; Daiji Yoshikawa; Hideo Izawa; Seiichi Matsuo; Yutaka Oiso; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2014-08-24       Impact factor: 2.037

Review 4.  Engineered nanomaterial-induced lysosomal membrane permeabilization and anti-cathepsin agents.

Authors:  Melisa Bunderson-Schelvan; Andrij Holian; Raymond F Hamilton
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017       Impact factor: 6.393

5.  Mast cell stabilization: novel medication for obesity and diabetes.

Authors:  Jing Wang; Guo-Ping Shi
Journal:  Diabetes Metab Res Rev       Date:  2011-11       Impact factor: 4.876

Review 6.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

7.  Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Vasileios C Kyttaris; Isaac E Stillman; Bruce Gelb; Peter Libby; George C Tsokos; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-01-16       Impact factor: 5.422

Review 8.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

9.  Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy.

Authors:  Yinan Hua; Xihui Xu; Guo-Ping Shi; Adam J Chicco; Jun Ren; Sreejayan Nair
Journal:  Hypertension       Date:  2013-03-25       Impact factor: 10.190

10.  Effects of cathepsin K deficiency on intercellular junction proteins, luminal mucus layers, and extracellular matrix constituents in the mouse colon.

Authors:  Maria Arampatzidou; André Schütte; Gunnar C Hansson; Paul Saftig; Klaudia Brix
Journal:  Biol Chem       Date:  2012-12       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.